(TheNewswire)
L ondon, Ontario - TheNewswire- February 25, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(Frankfurt/Xetra:PSH), a clinical-stage company and leader inregenerative medicine therapeutics is pleased to announce that the TSXVenture Stock Exchange (TSX Venture) has recognized Sernova as a 2021Venture 50 company, showcasing the top 50 performing listed companies.
“We are honoured to be chosen for the 2021 Venture 50 list and to beincluded amongst this distinguished group of industry leaders. Weshare this honour with our institutional and retail investors who aresupporting our continued success and growth,” said Dr. PhilipToleikis, President and CEO of Sernova Corp. “This recognition isanother validation of Sernova’s ongoing therapeutic advancements andbuilds upon what will be another very strong year as we continue togrow the company and build further shareholder value.”
The Venture 50 are the top ten companies listed on TSXVenture Exchange in each of five major industry sectors – mining,energy & energy services, clean technology & life sciences,diversified industries and technology – based on a ranking formulawith equal weighting given to market cap growth, trading volume amountand share price appreciation. All data was as of December 31,2020.
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch system including the Cell Pouch, which is a novel,proprietary, scalable, implantable macro-encapsulation device solutiondesigned for the long- term survival and function of therapeuticcells. The device is designed to incorporate with tissue, forminghighly vascularized tissue chambers for the transplantation andfunction of therapeutic cells which then release proteins and hormonesas required to treat disease. The Cell Pouch along with therapeuticcells has been shown to provide long-term safety and efficacy in smalland large animal models of diabetes and has been proven to provide abiologically compatible environment for insulin-producing cells inhumans. In early assessments of its ongoing Phase I/II clinical trial,Sernova has shown presence of blood levels of c-peptide both duringglucose tolerance tests as well as under fasting conditions. Clinicaltesting is ongoing at the University of Chicago.
ABOUT SERNOVA CORP
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells (i.e. human donor cells, corrected human cells and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visitwww.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words “expects”,“plans”, “anticipates”, “believes”, “intends”,“estimates”, “projects”, “potential” and similarexpressions, or that events or conditions “will”, “would”,“may”, “could” or “should” occur. Although Sernovabelieves the expectations expressed in such forward-looking statementsare based on reasonable assumptions, such statements are notguarantees of future performance, and actual results may differmaterially from those in forward-looking statements. Forward-lookingstatements are based on the beliefs, estimates, and opinions ofSernova’s management on the date such statements were made, whichinclude our beliefs about the conduct and outcome of clinical trials.Sernova expressly disclaims any intention or obligation to update orrevise any forward-looking statements whether as a result of newinformation, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.